Drug Trial Radar · NCT00555061
Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.
Last checked: Nov 20, 2026Latest source record: Dec 28, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Sep 2007
Primary completion
Aug 2008
Study completion Aug 2008
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Nov 7, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 months, up to 24 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to evaluate the pharmacokinetics of Retapamulin Ointment, 1%, in pediatric subjects (2-24 months) with secondarily-infected traumatic lesions, secondarily-infected dermatoses, or impetigo (bullous and non-bullous).
Conditions
- Skin Infections, Bacterial
Interventions
Retapamulin Ointment, 1%Drug
1% Ointment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Measurable Plasma Concentrations, by Age GroupTime frame: Days 3 to 4; 4 to 8 hours post-dose of the first dose of the day
Locations
25 sites in 9 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Tuscaloosa, Alabama
GSK Investigational Site
Bentonville, Arkansas
GSK Investigational Site
Orange, California
GSK Investigational Site
Woburn, Massachusetts
GSK Investigational Site
Cleveland, Ohio
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
GSK Investigational Site
Santiago, Región Metro de Santiago, Chile
GSK Investigational Site
San José, Costa Rica
GSK Investigational Site
Nördlingen, Bavaria, Germany
GSK Investigational Site
Bochum, North Rhine-Westphalia, Germany
GSK Investigational Site
Erkrath, North Rhine-Westphalia, Germany
GSK Investigational Site
Goch, North Rhine-Westphalia, Germany
GSK Investigational Site
Kleve-Materborn, North Rhine-Westphalia, Germany
GSK Investigational Site
México, Mexico
GSK Investigational Site
Alphen aan den Rijn, Netherlands
GSK Investigational Site
Losser, Netherlands
GSK Investigational Site
Roelofarendsveen, Netherlands
GSK Investigational Site
Rotterdam, Netherlands
GSK Investigational Site
Soerendonk, Netherlands
GSK Investigational Site
Woerden, Netherlands
GSK Investigational Site
Benoni, South Africa
GSK Investigational Site
Newtown, South Africa
GSK Investigational Site
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.